Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Andrew J. Aguirre, Brian M. Wolpin et al.|Cancer Discovery|2024Cited by 234
Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancerReid T. Powell, Helen Piwnica‐Worms, Abena B. Redwood et al.|Scientific Reports|2020Cited by 22
Supplemental Table 2 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Megan T. Hoffman et al.|Unknown|2024Cited by 0
Supplemental Table 1 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Megan T. Hoffman et al.|Unknown|2024Cited by 0
Supplemental Table 7 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Megan T. Hoffman et al.|Unknown|2024Cited by 0